1020 First Avenue
King of Prussia
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
327 articles with CSL Behring
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted [01-July-2019] MELBOURNE, Australia , July 1, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting
Global biotherapeutics leader CSL Behring announced that it will support the presentation of eight scientific posters at the 2019 annual meeting of the Peripheral Nerve Society (PNS), to be held 22-26 June, in Genoa, Italy.
Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
New vial options deliver on CSL Behring's heritage of innovation by providing more alternatives to patients
Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), basically a rejection, to Netherlands-based Pharming Group for its supplemental Biologics License Application (sBLA) for Ruconest.
The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of Stanley Iyadurai, M.D., Ph.D. as Vice President of Clinical Development.
CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP
A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant
Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.
IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions
Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing between patients with rare bleeding disorders and access to care.
CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM - Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) clinical trial and the first patient enrollment.
FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
Life Sciences Pennsylvania recognized CSL Behring's commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
CSL Behring Advances to Phase III Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy
The study will enroll more than 17,000 patients from approximately 1,000 sites around the world to evaluate whether CSL112 reduces cardiovascular events in high-risk patients during the critical 90 days after a heart attack.
CSL Limited and Vitaeris today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab as a therapeutic option for solid organ transplant rejection.
Lancet Neurology Publishes Results From CSL Behring Phase III Study of Hizentra to Treat Patients With Chronic Inflammatory Demyelinating Polyneuropathy
The Hizentra PATH study is the largest controlled clinical study in patients with CIDP.
Data on the Preventive Effects of HAEGARDA in Subjects With Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA reduced the median number of HAE attacks per month by 98 percent in subjects who had frequent attacks, from a 16-week placebo period to a 16-week treatment period.